Literature DB >> 30421364

Outcome differences between recanalized malignant central airway obstruction from endoluminal disease versus extrinsic compression.

Akash Verma1, Soon Keng Goh2, Dessmon Y H Tai2, Ai Ching Kor2, John Abisheganaden2, Zin Nge Nge Sein2, Wee See Yap2, Alan W K Ng2.   

Abstract

We compared the outcome of Nd:YAG laser therapy with stent placement for malignant central airway obstruction (CAO) at our center over a 10-year period. This is a retrospective review of patients undergoing Nd:YAG laser therapy or self-expanding metal stent (SEMS) placement for malignant CAO between November 2007 and October 2017. Seventy-two patients were recanalized for malignant CAO. The median (range) age was 63 (23-86) years, with 49 (68%) males. Patients underwent either laser therapy alone (N = 36), stent placement alone (N = 30), or both (N = 6). The wavelength of Nd:YAG laser used was 1064 nm, and median (range) laser energy used was 25 (15-35) W, in 377 (115-1107) pulses. Fifty-one (71%) patients died with median survival of 7.2 months. In subgroup analysis, 21 (58.3%) vs. 25 (83.3%), p = 0.03 patients died in the "laser resection" vs. "stent placement" group with longer median survival of 12.4 months in the former vs. 4.5 months, p = 0.0004 in the later. Esophageal cancer and left main bronchus involvement were significantly more common (10 (33.3%) vs. 0, p = 0.0001, and 16 (53.3%) vs. 8 (22.2%), p = 0.01), in the stent placement vs. laser resection group, respectively. Trachea or main bronchi involvement and respiratory failure on presentation requiring mechanical ventilation correlated with poorer survival. The immediate restoration of luminal patency, complication rate, and 30-day mortality was similar among the two groups. The median (range) energy used for laser therapy was 25 (15-35) W. Median of 377 pulses was used for the duration of 287.5 s. The results were compared using a Wilcoxon two-sample test, and Fischer exact test with p values considered indicative of a significant difference if less than 0.05. In patients requiring recanalization of malignant CAO, the extrinsic compression from esophageal cancer, trachea or main bronchi involvement, respiratory failure on presentation requiring mechanical ventilation, and stent placement correlated with poorer survival. Interventional pulmonology training program should emphasize on dedicated training in laser therapy as it is associated with improved survival.

Entities:  

Keywords:  Bronchoscopy; Cancer (lung); Esophagus; Stent; Trachea

Mesh:

Year:  2018        PMID: 30421364     DOI: 10.1007/s10103-018-2684-5

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


  4 in total

1.  Letter about outcome differences between recanalized malignant central airway obstruction from endoluminal disease versus extrinsic compression.

Authors:  Yahua Li; Jianzhuang Ren; Jianjian Chen; Xinwei Han
Journal:  Lasers Med Sci       Date:  2019-02-28       Impact factor: 3.161

2.  Prognostic factors for survival after bronchoscopic intervention in patients with airway obstruction due to primary pulmonary malignancy.

Authors:  Bo-Guen Kim; Beomsu Shin; Boksoon Chang; Hojoong Kim; Byeong-Ho Jeong
Journal:  BMC Pulm Med       Date:  2020-02-27       Impact factor: 3.317

3.  Predictors of survival and technical success of bronchoscopic interventions in malignant airway obstruction.

Authors:  Cláudia Freitas; Mariana Serino; Catarina Cardoso; Sandra Saleiro; Ana Paula Vaz; Hélder Novais-Bastos; António Morais; Adriana Magalhães; Gabriela Fernandes
Journal:  J Thorac Dis       Date:  2021-12       Impact factor: 2.895

4.  First-In-Human Computer-Optimized Endobronchial Ultrasound-Guided Interstitial Photodynamic Therapy for Patients With Extrabronchial or Endobronchial Obstructing Malignancies.

Authors:  Nathaniel M Ivanick; Emily R Oakley; Rajesh Kunadharaju; Craig Brackett; David A Bellnier; Lawrence M Tworek; Sergei N Kurenov; Sandra O Gollnick; Alan D Hutson; Theresa M Busch; Gal Shafirstein
Journal:  JTO Clin Res Rep       Date:  2022-06-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.